Is antiviral treatment at the acute phase of COVID-19 effective for decreasing the risk of long-COVID? A systematic review
Purpose Preliminary evidence suggests a potential effect of antiviral medication used during the acute COVID-19 phase for preventing long-COVID. This review investigates if having received pharmacological treatment during acute SARS-CoV-2 infection may reduce the risk of long-COVID. Methods MEDLINE, CINAHL, PubMed, EMBASE, Web of Science databases, as well as medRxiv/bioRxiv preprint servers were searched up to July 15th, 2023. Articles comparing the presence of long-COVID symptoms between individuals who received or not a specific medication, particularly antivirals, during the acute phase of SARS-CoV-2 infection were included. Methodological quality was assessed using the Newcastle–Ottawa Scale or Cochrane’s Risk of Bias (RoB) tool. Results From 517 studies identified, 6 peer-reviewed studies and one preprint met all inclusion criteria. The sample included 2683 (n = 4) hospitalized COVID-19 survivors and 307,409 (n = 3) non-hospitalized patients. The methodological quality was high in 71% of studies (n = 5/7). Two studies investigating the effects of Nirmatrelvir/Ritonavir and three studies investigating the effect of Remdesivir reported conflicting results on effectiveness for preventing long-COVID. Three studies investigating the effects of other medication such as Dexamethasone (n = 2) or Metformin (n = 1) found positive results of these medications for preventing long-COVID. Conclusion Available evidence about the effect of medication treatment with antivirals during acute COVID-19 and reduced risk of developing long-COVID is conflicting. Heterogeneous evidence suggests that Remdesivir or Nirmatrelvir/Ritonavir could have a potential protective effect for long-COVID. A limited number of studies demonstrated a potential benefit of other medications such as Dexamethasone or Metformin, but more studies are needed..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:52 |
|---|---|
| Enthalten in: |
Infection - 52(2023), 1 vom: 19. Dez., Seite 43-58 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fernández-de-las-Peñas, César [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Antiviral |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s15010-023-02154-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR054529484 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR054529484 | ||
| 003 | DE-627 | ||
| 005 | 20240309064730.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240126s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s15010-023-02154-0 |2 doi | |
| 035 | |a (DE-627)SPR054529484 | ||
| 035 | |a (SPR)s15010-023-02154-0-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Fernández-de-las-Peñas, César |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Is antiviral treatment at the acute phase of COVID-19 effective for decreasing the risk of long-COVID? A systematic review |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Purpose Preliminary evidence suggests a potential effect of antiviral medication used during the acute COVID-19 phase for preventing long-COVID. This review investigates if having received pharmacological treatment during acute SARS-CoV-2 infection may reduce the risk of long-COVID. Methods MEDLINE, CINAHL, PubMed, EMBASE, Web of Science databases, as well as medRxiv/bioRxiv preprint servers were searched up to July 15th, 2023. Articles comparing the presence of long-COVID symptoms between individuals who received or not a specific medication, particularly antivirals, during the acute phase of SARS-CoV-2 infection were included. Methodological quality was assessed using the Newcastle–Ottawa Scale or Cochrane’s Risk of Bias (RoB) tool. Results From 517 studies identified, 6 peer-reviewed studies and one preprint met all inclusion criteria. The sample included 2683 (n = 4) hospitalized COVID-19 survivors and 307,409 (n = 3) non-hospitalized patients. The methodological quality was high in 71% of studies (n = 5/7). Two studies investigating the effects of Nirmatrelvir/Ritonavir and three studies investigating the effect of Remdesivir reported conflicting results on effectiveness for preventing long-COVID. Three studies investigating the effects of other medication such as Dexamethasone (n = 2) or Metformin (n = 1) found positive results of these medications for preventing long-COVID. Conclusion Available evidence about the effect of medication treatment with antivirals during acute COVID-19 and reduced risk of developing long-COVID is conflicting. Heterogeneous evidence suggests that Remdesivir or Nirmatrelvir/Ritonavir could have a potential protective effect for long-COVID. A limited number of studies demonstrated a potential benefit of other medications such as Dexamethasone or Metformin, but more studies are needed. | ||
| 650 | 4 | |a Antiviral |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Remdesivir |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Nirmatrelvir/Ritonavir |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Long-COVID |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Post-COVID-19 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Review |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Torres-Macho, Juan |4 aut | |
| 700 | 1 | |a Catahay, Jesus Alfonso |4 aut | |
| 700 | 1 | |a Macasaet, Raymart |4 aut | |
| 700 | 1 | |a Velasco, Jacqueline Veronica |4 aut | |
| 700 | 1 | |a Macapagal, Sharina |4 aut | |
| 700 | 1 | |a Caldararo, Mario |4 aut | |
| 700 | 1 | |a Henry, Brandon Michael |4 aut | |
| 700 | 1 | |a Lippi, Giuseppe |4 aut | |
| 700 | 1 | |a Franco-Moreno, Ana |4 aut | |
| 700 | 1 | |a Notarte, Kin Israel |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Infection |d München : Urban & Vogel, 1973 |g 52(2023), 1 vom: 19. Dez., Seite 43-58 |w (DE-627)SPR032536909 |w (DE-600)2006315-5 |x 1439-0973 |7 nnns |
| 773 | 1 | 8 | |g volume:52 |g year:2023 |g number:1 |g day:19 |g month:12 |g pages:43-58 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s15010-023-02154-0 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 52 |j 2023 |e 1 |b 19 |c 12 |h 43-58 | ||